Search Results

You are looking at 51 - 60 of 363 items for :

  • Refine by Access: All x
Clear All
Full access

What, When, and How of Biomarker Testing in Non–Small Cell Lung Cancer

Gregory L. Riely

( EGFR )–mutant NSCLC, he emphasized. The 2017 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for NSCLC recommend biomarker testing for all patients who present with stage IV disease. Molecular testing should be capable of identifying

Full access

Management of Patients With Resectable and Metastatic Non–Small Cell Lung Cancer

Presented by: Jane Yanagawa and Gregory J. Riely

completely resected stage IB–IIIA EGFR -mutation–positive disease (exon 19 del or L858R) were randomly assigned to adjuvant osimertinib or placebo for 3 years. 6 At 2 years, 90% of patients with stage II–IIIA disease who received adjuvant osimertinib were

Full access

Volume 7 (2009): Issue Suppl_1 (May 2009): NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated With EGFR Inhibition in Patients With Cancer

Full access

Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary) Primary Liver Carcinoma

Amy Zhou, Manik Amin, Kathryn J. Fowler, Elizabeth M. Brunt, Jesse Keller, and Benjamin Tan

combination of an epidermal growth factor receptor (EGFR) inhibitor and a vascular endothelial growth factor (VEGF) inhibitor. Case Presentation During a workup for chest pain in a 77-year-old Caucasian woman, a 3-cm liver lesion was found incidentally

Full access

NCCN Task Force Report: mTOR Inhibition in Solid Tumors

Robert A. Figlin, Elizabeth Brown, Andrew J. Armstrong, Wallace Akerley, Al B. Benson III, Harold J. Burstein, David S. Ettinger, Phillip G. Febbo, Matthew G. Fury, Gary R. Hudes, Merrill S. Kies, Eunice L. Kwak, Robert J. Morgan Jr., Joanne Mortimer, Karen Reckamp, Alan P. Venook, Frank Worden, and Yun Yen

combination with mTOR inhibitors in cancer therapy. Abbreviations: EGFR, epithelial growth factor receptor; HIF, hypoxia-inducible factors; MEK, mitogen-activated extracellular kinase; mTOR, mammalian target of rapamycin; PDGFR, platelet-derived growth factor

Full access

Non–Small Cell Lung Cancer, Version 6.2015

David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Thomas J. Dilling, M. Chris Dobelbower, Ramaswamy Govindan, Frederic W. Grannis Jr, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Lee M. Krug, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Steven E. Schild, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes

actionable genetic alterations: anaplastic lymphoma kinase ( ALK ) gene rearrangements and sensitizing epidermal growth factor receptor ( EGFR ) mutations. The complete version of the NCCN Guidelines addresses all aspects of management for NSCLC, including

Full access

Targeted/Emerging Therapies for Metastatic Non–Small Cell Lung Cancer

Leora Horn

factor receptor ( EGFR ) and anaplastic lymphoma kinase ( ALK ) mutational testing is a category 1 recommendation. If the histology is squamous cell carcinoma, the NCCN Guidelines suggest that both EGFR and ALK mutational testing be considered

Full access

Ancestry-, Sex-, and Age-Based Differences of Gene Alterations in NSCLC: From the Real-World Data of Cancer Genomic Profiling Tests

Keita Miura, Takehito Shukuya, Ray Greenstein, Ben Kaplan, Heather Wakelee, Kana Kurokawa, Kazuyuki Furuta, Shunsuke Kato, Junghee Suh, Smruthy Sivakumar, Ethan S. Sokol, David P. Carbone, and Kazuhisa Takahashi

, we investigated genomic alteration prevalence in a large real-world NSCLC cohort, stratified by genetic ancestry, as well as sex and age. In addition, the efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib have been reported

Full access

Non–Small Cell Lung Cancer: Recommendations for Biomarker Testing and Treatment

Presented by: Dara L. Aisner and Gregory J. Riely

found that the third-generation EGFR tyrosine kinase inhibitor (TKI) osimertinib improved 3-year disease-free survival in stage IB–III, EGFR -positive NSCLC. 4 “This study galvanized the push for earlier testing in NSCLC,” Dr. Aisner stated. The 2021

Full access

Sequencing Therapy for Patients With Lung Cancer

Presented by: Gregory J. Riely

classified according to mutations and gene fusions. The guidelines highlight some key molecular subtypes that should be included in molecular testing: EGFR sensitizing mutations, ALK gene rearrangements, ROS1 rearrangements, BRAF mutations, RET